Page 1

RnR Market Research Offers “Lee’s Pharmaceutical Holdings Limited – Product Pipeline Review – 2012” Report at US$ 1500 (Single User License). The report got published in Nov 2012 & contains 80 pages.

Lee’s Pharmaceutical Holdings Limited – Product Pipeline Review – 2012 Summary RnR Market Research pharmaceuticals report, “Lee’s Pharmaceutical Holdings Limited – Product Pipeline Review – 2012″ provides data on the Lee’s Pharmaceutical Holdings Limited’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from RnR Market Research proprietary databases, Lee’s Pharmaceutical Holdings Limited’s corporate website, SEC filings, investor presentations and featured press releases, both from Lee’s Pharmaceutical Holdings Limited and industry-specific third party sources, put together by RnR Market Research team. Scope        

Lee’s Pharmaceutical Holdings Limited – Brief Lee’s Pharmaceutical Holdings Limited overview including business description, key information and facts, and its locations and subsidiaries. Review of current pipeline of Lee’s Pharmaceutical Holdings Limited human therapeutic division. Overview of pipeline therapeutics across various therapy areas. Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. Product profiles for late stage and clinical stage products of Lee’s Pharmaceutical Holdings Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. Recent updates of the Lee’s Pharmaceutical Holdings Limited’s pipeline in the last quarter. Key discontinued and dormant projects. Latest news and deals relating to the products.

Get your report copy of this report @ http://www.rnrmarketresearch.com/the-chinese-rd-landscapechemical-engineering-2-market-report.html Reasons to buy     

Evaluate Lee’s Pharmaceutical Holdings Limited’s strategic position with total access to detailed information on its product pipeline. Assess the growth potential of Lee’s Pharmaceutical Holdings Limited in its therapy areas of focus. Identify new drug targets and therapeutic classes in the Lee’s Pharmaceutical Holdings Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. Exploit collaboration and partnership opportunities with Lee’s Pharmaceutical Holdings Limited.


 

Avoid Intellectual Property Rights related issues. Explore the dormant and discontinued projects of Lee’s Pharmaceutical Holdings Limited and identify potential opportunities in those areas.

Table Of contents Table of Contents 2 List of Tables 6 List of Figures 6 Lee's Pharmaceutical Holdings Limited Snapshot 7 Lee's Pharmaceutical Holdings Limited Overview 7 Key Information 7 Key Facts 7 Lee's Pharmaceutical Holdings Limited - Research and Development Overview 8 Key Therapeutic Areas 8 Lee's Pharmaceutical Holdings Limited - Pipeline Review 12 Pipeline Products by Stage of Development 12 Pipeline Products - Monotherapy 13 Lee's Pharmaceutical Holdings Limited - Pipeline Products Glance 14 Lee's Pharmaceutical Holdings Limited - Late Stage Pipeline 14 Registration Filed Products/Combination Treatment Modalities 14 Phase III Products/Combination Treatment Modalities 15 Lee's Pharmaceutical Holdings Limited Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Lee's Pharmaceutical Holdings Limited - Early Stage Pipeline Products 18 Pre-Clinical Products/Combination Treatment Modalities 18 Lee's Pharmaceutical Holdings Limited - Drug Profiles 19 Acetylcarnitine 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Declotana 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 istaroxime 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 JX-594 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 levocarnitine propionate hydrochloride 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 NOV-205 26 Product Description 26 Mechanism of Action 26 R&D Progress 26


paroxetine hydrochloride 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 procarbazine hydrochloride 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 prulifloxacin 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 RGN-137 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 RGN-259 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 RGN-352 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 rostafuroxin 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 treprostinil 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 ZK-002 39 Product Description 39 Mechanism of Action 41 R&D Progress 41 ZK-006 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ZK-008 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 ZK007 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Lee's Pharmaceutical Holdings Limited - Pipeline Analysis 45 Lee's Pharmaceutical Holdings Limited - Pipeline Products by Therapeutic Class 45 Lee's Pharmaceutical Holdings Limited - Pipeline Products by Route of Administration 46 Lee's Pharmaceutical Holdings Limited - Pipeline Products By Mechanism of Action 47


Lee's Pharmaceutical Holdings Limited - Recent Pipeline Updates 48 Lee's Pharmaceutical Holdings Limited - Dormant Projects 53 Lee's Pharmaceutical Holdings Limited - Locations And Subsidiaries 54 Head Office 54 Lee's Pharmaceutical Holdings Limited, Recent Developments 55 Lee's Pharmaceutical Holdings Limited- Press Release 55 Jul 31, 2012: Lee's Pharma Enrolls First Patient In Phase Ib/IIa Clinical Study Of Anfibatide To Treat Acute Coronary Syndrome 55 Jun 28, 2012: Lee's Pharma Completes Phase III Clinical Study Of L-Carnitine In Chronic Heart Failure Patients 56 Financial Deals Landscape 57 Lee's Pharmaceutical Holdings Limited, Deals Summary 57 Lee's Pharmaceutical Holdings Limited, Pharmaceuticals & Healthcare, Deal Details 59 Asset Transactions 59 Powder Pharma And Lee's Pharma Acquire Rights & Related Assets Of Zingo From Anesiva 59 Partnerships 61 Lee's Pharma Enters Into Distribution Agreement With CID 61 United Therapeutics Enters Into Distribution Agreement With Lee's Pharma 63 Leepharm Enters Into Co-Marketing Agreement With Italfarmaco 65 Lee's Pharma Holdings Enters Into Distribution Agreement With Helsinn 66 Lee's Pharma Enters Into Distribution Agreement With Italfarmaco 67 Lee's Pharma Enters Into Distribution Agreement With APOGEPHA 68 Licensing Agreements 69 RegeneRx Biopharma Enters Into Licensing Agreement With Lee's Pharma For RGN-259, RGN-352 And RGN-137 69 PLx Pharma Enters Into Licensing Agreement With Lee's Pharma For Cardiovascular Product 72 Recordati Enters Into Licensing Agreement With Lee's Pharma 73 Jennerex Enters Into Collaboration And License Agreement With Lee's Pharma Holdings 74 Nippon Shinyaku Enters Into Licensing Agreement With Lee's Pharma Holding 75 Anesiva Enters Into An Agreement With Lee's Pharma 76 Novelos Therapeutics Enters Into Licensing Agreement With Lee's Pharma 77 Appendix 79 Methodology 79 Coverage 79 Secondary Research 79 Primary Research 79 Expert Panel Validation 79 Contact Us 80 Disclaimer 80 For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441 Website: http://www.rnrmarketresearch.com/

Lee’s Pharmaceutical Holdings Limited Product Pipeline Review to 2012  

RnR Market Research pharmaceuticals report, “Lee’s Pharmaceutical Holdings Limited – Product Pipeline Review – 2012″ provides data on the Le...

Read more
Read more
Similar to
Popular now
Just for you